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Background: Traditional NSAIDs (tNSAIDs) and COX-2 inhibitors (COX-2s) are important 
agents for the treatment of a variety or arthritic conditions. The purpose of this study was to 
systematically review the effectiveness of misoprostol, H2-receptor antagonists (H2RAs), and 
proton pump inhibitors (PPIs) for the prevention of tNSAID related upper gastrointestinal (GI) 
toxicity, and to review the upper gastrointestinal (GI) safety of COX-2s.
Methods: An extensive literature search was performed to identify randomized controlled 
trials (RCTs) of prophylactic agents used for the prevention of upper GI toxicity, and RCTs 
that assessed the GI safety of the newer COX-2s. Meta-analysis was performed in accordance 
with accepted techniques.
Results: 39 gastroprotection and 69 COX-2 RCTs met inclusion criteria. Misoprostol, PPIs, 
and double doses of H2RAs are effective at reducing the risk of both endoscopic gastric and 
duodenal tNSAID-induced ulcers. Standard doses of H2RAs are not effective at reducing the 
risk of tNSAID-induced gastric ulcers, but reduce the risk of duodenal ulcers. Misoprostol 
is associated with greater adverse effects than the other agents, particularly at higher 
doses. COX-2s are associated with fewer endoscopic ulcers and clinically important ulcer 
complications, and have fewer treatment withdrawals due to GI symptoms than tNSAIDS. 
Acetylsalicylic acid appears to diminish the benefit of COX-2s over tNSAIDs. In high risk 
GI patients, tNSAID with a PPI or a COX-2 alone appear to offer similar GI safety, but 
a strategy of a COX-2 with a PPI appears to offer the greatest GI safety.
Conclusion: Several strategies are available to reduce the risk of upper GI toxicity with 
tNSAIDs. The choice between these strategies needs to consider patients’ underlying GI and 
cardiovascular risk.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat arthritis, 
menstrual, musculoskeletal and post-operative pain, as well as headache and 
fever. NSAIDs include acetylsalicylic acid (ASA), traditional NSAIDs (tNSAIDs) 
(eg, diclofenac, ibuprofen, indomethacin, and naproxen) and inhibitors of the COX-2 
isoform of cyclo-oxygenase (referred to here as COX-2s, eg, celecoxib, lumiracoxib, 
etoricoxib, rofecoxib).
One cohort study found that about 25% of Canadians in 2001 were prescribed 
short-term NSAIDs (a rise of 28% over 1999 when COX-2s were first introduced), 
and about 4% were prescribed these agents long-term (defined in this study 
as 6 months);1 this equates to approximately 6.2 million short-term users, and 
1.0 million long-term users of NSAID therapy. However, this substantially underestimates Drug, Healthcare and Patient Safety 2009:1 48
Rostom et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
the true magnitude of NSAID uses since it does not include 
use of over the counter NSAIDs. A US cohort study, reported 
the point prevalence of daily prescription NSAID use as 
8.7% between 2002 and 2003 with 46% being COX-2s.2 
Low-dose ASA is extensively used for cardiovascular risk 
reduction.
There are increasing concerns over the risks of gas-
trointestinal and cardiovascular adverse events with these 
medications. The increased risks of upper gastrointestinal 
ulcers and complications with tNSAIDs and ASA are well 
documented,3–7 and while the risks are reduced by about 
50% with COX-2s, they continue to be important since this 
risk is not reduced to baseline.8–10 Furthermore with the 
introduction of COX-2s in the late 1990, overall NSAID 
prescriptions rose with COX-2s overtaking tNSAIDs 
suggesting that individuals not previously on NSAIDs 
were being prescribed COX-2s. Over the same time frame, 
there was a 75.9% increase in the rate of non-fatal digestive 
perforations and hemorrhages in the presence of NSAIDs. 
Moreover, the benefits of COX-2s are attenuated when 
COX-2s are co-prescribed with ASA10 although to a lesser 
extent than when tNSAIDs are co-prescribed with ASA. 
In addition, extensive data associate COX-2s and non-
naproxen tNSAIDs with an increased risk of cardiovascular 
events,11,12 which has led regulatory authorities to introduce 
warning statements and advisories Additionally, the COX-2s, 
rofecoxib, valdecoxib, and lumiracoxib have been withdrawn 
from the market because of cardiovascular, cutaneous, and 
hepatic adverse events respectively.1,2,13–15 Health Canada 
and the Food and Drug Administration (FDA) require the 
product information for tNSAIDs and COX-2s to include 
a warning of the increased incidence of cardiovascular 
(eg, heart attack, stroke) and gastrointestinal (eg, ulcer, 
bleeding) adverse events, as well as recommendations to 
limit use of the drug to the lowest effective dose for the 
shortest possible duration of treatment.2,15
The purpose of this study was to systematically review 
the literature on interventions to prevent tNSAID related 
upper gastrointestinal (GI) toxicity, and on the GI safety of 
COX-2s.
Methods
This review was conducted in accordance with the methods 
of the Cochrane Collaboration.16
Literature search strategy
The search strategy and methods have been previously 
described elsewhere. These were updated to May 2009.10,17
inclusion criteria
Types of studies
RCTs of COX-2s (celecoxib [Celebrex®], rofecoxib 
[Vioxx®], etoricoxib [Arcoxia®], valdecoxib [Bextra®], lumi-
racoxib [Prexige®]) were considered eligible for inclusion if 
the upper GI toxicity of these agents was compared to that 
of a non-selective NSAID or to placebo. RCTs of prosta-
glandin analogues (misoprostol), H2-receptor antagonists 
(H2RA), and proton pump inhibitors (PPI) in the prevention 
of NSAID-induced upper GI toxicity were also considered if 
these agents were used alongside an NSAID compared to an 
NSAID alone. Further the RCTs had to meet the following 
additional criteria.
Participants were 18 years or older and had osteoarthritis, 
rheumatoid arthritis or another arthritic condition; NSAID 
exposure was 4 weeks or longer (chronic NSAID exposure); 
the proportion of patients with endoscopic ulcers, significant 
clinical GI events (eg, perforation, obstruction, bleeding, 
symptomatic ulcers), and/or symptom based clinical events 
(adverse GI symptoms, withdrawals due to GI symptoms) 
could be determined; endoscopic ulcers were defined as 
being at least 3 mm in diameter or could be distinguished 
from erosions based on the authors’ descriptions; and it was 
noted whether endoscopy was performed based on symptoms 
or as part of a protocol.
Types of interventions
The interventions included the following COX-2s: celecoxib 
(Celebrex®), rofecoxib (Vioxx®), etoricoxib (Arcoxia®), 
valdecoxib (Bextra®), lumiracoxib (Prexige®). For this 
review, low-dose COX-2s were defined as celecoxib 200 mg 
bid or less, rofecoxib 25 mg daily or less, etoricoxib 60 mg 
daily or less, valdecoxib 10 mg daily or less, and lumiracoxib 
100 to 200 mg. High-dose COX-2s were defined as celecoxib 
400 mg bid, rofecoxib 50 mg daily, etoricoxib 90 mg daily 
or more, valdecoxib 20 mg daily or more, and lumiracoxib 
400 mg or more. For prophylaxis against tNSAID induced 
upper GI toxicity we included: the prostaglandin antagonist 
misoprostol (Cytotec®) (low dose 400 µg/day, intermediate 
dose 600 µg/day; high dose 800 µg/day); the PPIs 
omeprazole, esomeprazole, pantoprazole, and lansoprazole 
(Losec®, Nexium®, Pantoloc®, Prevacid®, respectively); and 
the H2RAs cimetadine, ranitidine, nizatidine, and famotidine 
(Tagamet®, Zantac®, Axid®, and Pepcid®, respectively). 
Double doses of H2RAs were defined as a dose equivalent to 
or greater than 300 mg of ranitidine twice daily, and standard 
dose of PPIs were considered the equivalent of 20 mg of 
omeprazole once daily.Drug, Healthcare and Patient Safety 2009:1 49
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Types of outcome measures
The primary outcomes were: endoscopically detected 
ulcer in endoscopy trials; and clinical GI events. Clinically 
important adverse events were categorized in two ways: 
1) strict ulcer complications, which are referred to as 
“POB” (for perforation, obstruction or bleeding), and 
2) ulcer complications and/or ulcer-related symptoms that 
lead to the identification of an ulcer (so called symptomatic 
ulcer), which are referred to as “PUB” (for perforation, 
obstruction, bleeding or the presence of a symptomatic 
ulcer). Efficacy/tolerability trials were defined as studies that 
focused on clinical efficacy or effectiveness of COX-2s but 
also reported on adverse symptoms or other clinical adverse 
events. Secondary outcomes were: adverse GI symptoms 
(dyspepsia, nausea, abdominal pain, or diarrhea); and 
treatment withdrawals due to GI symptoms.
Quality assessment
All RCTs were scored for quality by 2 independent 
reviewers using the Jadad scale.18 The quality of allocation 
concealment was also assessed.19 Differences were resolved 
by consensus.
Statistical analysis
Data were analyzed using Review Manager (RevMan) 
version 5.0. Endoscopic, clinical and symptom-based outcomes 
were analyzed separately. The primary analyses were expressed 
as relative risks using a fixed effects model. A random-effects 
model was used to combine “heterogeneous trials” only 
if it was clinically and statistically appropriate. The absolute 
risk reduction (ARR ) was calculated for appropriate clinical 
endpoints.
Subgroup analyses
Studies were grouped by interventions (eg, COX-2s vs 
tNSAIDs, and COX-2s vs placebo), dosage (low-dose and 
high-dose), and duration of therapy. Additionally, within 
each of the three main outcome analyses (endoscopic ulcer, 
clinical ulcer, and symptoms), studies were analyzed as all 
COX-2s vs all tNSAIDs, individual COX-2s vs all comparator 
tNSAIDs, individual tNSAIDs vs all comparator COX-2s, 
and individual COX-2s vs individual tNSAIDs.
Heterogeneity
Sources for clinical and statistical heterogeneity were sought 
prior to statistical analyses. Logical analyses subgroups were 
created (see above) to allow for more homogeneous analyses 
groups. Heterogeneity was tested using the I2 statistic and 
a chi-square test. An I2  50% or a chi-square p value of 
less than 0.10 is considered to be evidence of statistical 
heterogeneity.20
Sensitivity analyses
In addition to the published reports, unique studies were 
identified from the FDA web site, and in the form of published 
“combined analyses” studies. The latter studies combined 
published and unpublished primary patient data from the 
endoscopic studies, as well as the safety and tolerability 
studies to allow sample sizes large enough to comment 
on clinical ulcer complications. We carefully examined 
these studies by their ID number, their sample size, patient 
demographics and list of authors and cross referenced with 
the FDA web site in order to ensure that their use in the 
ulcer complication analyses would not create duplication of 
individual patient data. Sensitivity analyses were conducted 
removing or adding FDA studies, and the combined analyses 
studies. Additionally, sensitivity analyses were used to 
assess the impact of supplemental FDA data on published 
study results when available (eg, CLASS study). Sensitivity 
analysis was also performed removing studies with quality 
scores of 2 or less.
Results
Part i – tNSAiD prophylaxis
Of a total of 1205 references with 256 being potentially 
relevant, 39 RCTs met the inclusion criteria: 23 misoprostol 
trials (includes 6 head to head studies); 12 H2RA (9 standard 
dose, 3 double dose, 1 head to head); and 9 PPI trials 
(6 direct, 5 head to head). Some studies considered more 
than one active intervention. Table 1 summarizes the 
characteristics of the included studies. Effects of interventions 
are summarized below.
Misoprostol
We found 23 studies that assessed the long term effect of 
misoprostol on the prevention of tNSAID ulcers.14,21–42
endoscopic ulcers
Eleven studies with 3,641patients compared the incidence 
of endoscopic ulcers, after at least 3 months, of misoprostol 
to that of placebo.21,22,25,29–33,36,38,42 The cumulative incidence 
of endoscopic gastric and duodenal ulcers with placebo 
were 15% and 6% respectively. Misoprostol (any dose 
combined) significantly reduced the relative risk of gastric 
ulcer and duodenal ulcers by 74% relative risk [RR] 0.26; 
95% confidence interval [CI] 0.17 to 0.39, random effects), Drug, Healthcare and Patient Safety 2009:1 50
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Table 1 included studies of gastro-protection
Study Comparisons 
 
NSAID Number Mean age Primary or 
secondary
Follow-up 
times 
(months)
Intervention Comparator
Misoprostol
Graham30 misoprostol 400 µg/day placebo ibuprofen, piroxicam, 
naproxen
421 59 primary 1, 2, 3
misoprostol 800 µg/day
Agrawal21 misoprostol 800 µg/day placebo various 356 60 primary 3
Chandrasekaran26 misoprostol 600 µg/day placebo various 90 39 primary 1
Saggioro39 misoprostol 800 µg/day placebo various 166 56 primary 1
Bolten24 misoprostol 400–600 µg/day placebo diclofenac 361 60 primary 1
verdickt42 misoprostol 400–600 µg/day placebo diclofenac 339 53 primary 3
Melo14 misoprostol 400 µg/day +  
diclofenac
placebo + 
piroxicam
piroxicam 643 60 primary 1
Graham31 misoprostol 800 placebo various 643 59 primary 3
Henriksson34 misoprostol 600 µg/day placebo naproxen, ibuprofen, 
aspirin
40 60 primary 1
Roth38 misoprostol 800 placebo ibuprofen 113 53 and 60 primary 3
Delmas28 misoprostol 400 µg/day placebo various 256 54 primary 1
misoprostol 800 µg/day
elliott29 misoprostol 600–800 µg/day placebo various 83 65 primary 3, 6, 12
Agrawal22 misoprostol 400–600 µg/day placebo diclofenac 384 57 secondary 3, 6, 12
Raskin36 misoprostol 400 µg/day placebo various 1618 58 primary 3
misoprostol 600 µg/day
misoprostol 800 µg/day
Silverstein40 misoprostol 800 µg/day placebo various 8843 68 primary 24
Bocanegra23 misoprostol 200 µg bid 
misoprostol 200 µg tid
placebo diclofenac 481 62 primary 1
Chan25 misoprostol 200 bid nabumetone naproxen 90 74 secondary 6
H2 antagonists
Berkowitz43 ranitidine 150 mg bid placebo aspirin 50 28.5 primary 1
Roth140 cimetidine 400 mg/day placebo various 26 nd primary 10
ehsanullah44 ranitidine 150 mg bid placebo various 297 57 primary 1, 2
Robinson46 ranitidine 150 mg bid placebo various 144 48 primary 1, 2
Swift50 ranitidine 150 mg bid placebo various 24 56.5 primary 4
Robinson45 ranitidine 150 mg/day placebo 227 54.2 primary 1
Levine49 nizatidine 150 mg bid placebo 496 56.9 primary 3
Simon51 nizatidine 150 mg/day nizatidine  
150 mg bid
237 58 secondary 3, 6
Taha47 famotidine 20 mg/day primary 1, 3, 6
famotidine 40 mg/day placebo various 285 53.4
wolde53 ranitidine 300 bid placebo 30 67 ranitidine, 
58 placebo
secondary 12
van Groenendael48 ranitidine 150 mg bid (Grp B) placebo various 36 52 primary 1
Hudson52 famotidine 40 mg bid placebo various 78 58 secondary 1, 3, 6
(Continued)Drug, Healthcare and Patient Safety 2009:1 51
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Table 1 (Continued)
Study Comparisons 
 
NSAID Number Mean age Primary or 
secondary
Follow-up 
times 
(months)
Intervention Comparator
Proton pump inhibitors
Cullen55 omeprazole 20 mg/day placebo 168 primary 6
ekstrom56 omeprazole 20 mg/day placebo various 177 58 primary 3
Hawkey85 misoprostol 400 µg/day 
omeprazole 20 mg/day
placebo diclofenac, ketoprofen, 
naproxen
725 58 secondary 6
Bianchi Porro54 pantoprazole 40 mg/day placebo various 104 58 primary 3
Lai57 lansoprazole 30 mg placebo naproxen 43 69 secondary 2
Head to head comparisons
valentini41 misoprostol 400 diclofenac 61 59.2 44% n/a
ranitidine 150 mg bid
Raskin37 misoprostol 800 µg/day ranitidine  
150 mg bid
various 538 61 primary 2
Hawkey85 misoprostol 400 µg/day 
omeprazole 20 mg/day
placebo diclofenac, ketoprofen, 
naproxen
725 58 secondary 6
Yeomans58 omeprazole 20 mg/day ranitidine  
150 mg bid
diclofenac, 
indomethacin, 
naproxen
425 56 30% 1, 2
Jensen35 misoprostol 200 µg qid omeprazole 
20 mg bid
various 46 n/a secondary 6
Graham32 misoprostol 800 µg 
lansoprazole 15 mg 
lansoprazole 30 mg
placebo various 537 60 secondary 3
Stupnicki13 misoprostol 400 µg/day pantoprazole 
40 mg/day
diclofenac 515 55 primary 1
and 58% (RR 0.42; 95% CI 0.22 to 0.81, random effects). 
These relative risks correspond to a 12.0%, and 3% absolute 
risk reductions for gastric and duodenal ulcers respectively. 
The observed heterogeneity in these estimates was due to 
inclusion of all misoprostol doses in the analyses. Analysis 
of the misoprostol studies stratified by dose eliminated this 
heterogeneity.
Analysis by dose
All the studied doses of misoprostol significantly reduced the 
risk of endoscopic ulcers, and a dose response relationship 
was demonstrated for endoscopic gastric ulcers. Six studies 
with 2,461 patients used misoprostol 400 µg.22,25,30,33,36,42 
1 study with 928 patients used 600 µg daily,36 and 7 with 
2,423 patients used 800 µg daily.21,29–32,36,38 Misoprostol 
800 µg daily was associated with the lowest risk (RR 0.17; 
95% CI 0.11 to 0.24) of endoscopic gastric ulcers when 
compared to placebo, whereas misoprostol 400 ug daily 
was associated with a relative risk of 0.42 (95% CI 0.28 to 
0.67, random effects model for heterogeneity) (Figure 1). 
This difference between high- and low-dose misoprostol 
reached statistical significance (P0.0055). The intermediate 
misoprostol dose (600 µg daily) was not statistically different 
from either the low or high dose. The pooled relative risk 
reduction of 78% (4.7% absolute risk difference, RR 0.21; 
95% CI 0.09 to 0.49) for duodenal ulcers with misoprostol 
800 µg daily was not statistically different from those of the 
lower daily misoprostol dosages.
Studies including data with less than 3 months 
tNSAiD exposure
Eight studies, with 2,206 patients, assessed the rates of 
endoscopic ulcers with misoprostol compared to placebo at 
1 to 1.5 months.14,23,24,26,28,29,34,39 The pooling of these studies 
revealed an 81% relative risk reduction of gastric ulcers with 
misoprostol (RR 0.17; 95% CI 0.09 to 0.31) and an 72% 
relative risk reduction of duodenal ulcers (RR 0.28; 95% 
CI 0.14 to 0.56).
One study compared misoprostol to a newer cytoprotective 
agent, dosmafate, for tNSAID prophylaxis and found no Drug, Healthcare and Patient Safety 2009:1 52
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Study or Subgroup
4.4.1 Low dose (400−600 µg)
Agrawal22
Chan25
Graham30
Hawkey33
Raskin36
Verdickt42
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 10.97, df = 5 (P = 0.05); I² = 54%
Test for overall effect: Z = 6.88 (P < 0.00001)
4.4.2 Mid-range dose (600 µg)
Raskin36
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.64 (P < 0.00001)
4.4.3 High dose (800 µg)
Agrawal21
Elliott29
Graham30
Graham31
Graham32
Raskin36
Roth38
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 6.71, df = 6 (P = 0.35); I² = 11%
Test for overall effect: Z = 9.28 (P < 0.00001)
Events
6
5
8
31
29
4
83
13
13
2
4
2
6
8
6
0
28
Total
193
45
143
296
462
164
1303
474
474
179
40
140
320
111
228
60
1078
Events
20
2
30
50
51
6
159
51
51
21
11
30
25
54
51
7
199
Total
191
45
138
155
454
175
1158
454
454
177
43
138
323
111
454
53
1299
Weight
11.5%
1.1%
17.4%
37.4%
29.3%
3.3%
100.0%
100.0%
100.0%
11.5%
5.8%
16.5%
13.6%
29.5%
18.6%
4.4%
100.0%
M-H, Fixed, 95% CI
0.30 [0.12, 0.72]
2.50 [0.51,12.22]
0.26 [0.12, 0.54]
0.32 [0.22, 0.49]
0.56 [0.36, 0.87]
0.71 [0.20, 2.48]
0.42 [0.32, 0.53]
0.24 [0.13, 0.44]
0.24 [0.13, 0.44]
0.09 [0.02, 0.40]
0.39 [0.14, 1.13]
0.07 [0.02, 0.27]
0.24 [0.10, 0.58]
0.15 [0.07, 0.30]
0.23 [0.10, 0.54]
0.06 [0.00, 1.01]
0.17 [0.11, 0.24]
Misoprostol Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.02 0.1 1 10 50
Favors misoprostol Favors control
Figure 1 Misoprostol vs placebo for the prevention of gastric ulcers – efficacy by dose.
statistically significant difference in ulcer rates between 
the two agents.27
Clinical ulcers
Only 1 RCT, the MUCOSA trial, evaluated the efficacy 
of misoprostol prophylaxis against clinically important 
TNSAID induced ulcer complications as the powered 
primary endpoint. In this study, of 8,843 patients studied over 
6 months, the overall GI event incidence was about 1.5% per 
year.40 Misoprostol 800 µg/day was associated with a statisti-
cally significant 40% risk reduction (odds ratio0.598; 95% CI 
0.364 to 0.982) in combined GI events (P0.049), representing 
a risk difference of 0.38% (from 0.95% to 0.57%).
Adverse effects
Misoprostol was associated with a small but statistically 
significant 1.6 fold excess risk of drop out due to drug induced 
side effects, and an excess risk of drop-outs due to nausea 
(RR 1.30; 95% CI 1.08 to 1.55), diarrhea (RR 2.36; 95% CI 
2.01 to 2.77), and abdominal pain (RR 1.36; 95% CI 1.20 
to 1.55). In the MUCOSA trial, 732 out of 4,404 patients 
on misoprostol experienced diarrhea or abdominal pain, 
compared to 399 out of 4,439 on placebo for a relative risk 
of 1.82 associated with misoprostol (P  0.001). Overall 
27% of patients on misoprostol experienced one or more 
side effects.40
When analyzed by dose, only misoprostol 800 µg daily 
showed a statistically significant excess risk of drop-outs due 
to diarrhea (RR 2.45; 95% CI 2.09 to 2.88), and abdominal 
pain (RR 1.38; 95% CI 1.17 to 1.63 ). Both misoprostol doses 
were associated with a statistically significant risk of diarrhea. 
However, the risk of diarrhea with 800 µg/day (RR 3.25; 95% 
CI 2.60 to 4.06) was significantly higher than that seen with Drug, Healthcare and Patient Safety 2009:1 53
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400 µg/day (RR 1.81 95% CI 1.52 to 2.16) (P0.0012). The 
results for overall dropouts due to symptoms analyzed by 
dose are shown in Figure 2.
H2RAs
Seven trials with over 900 patients assessed the effect of 
standard dose H2RAs on the prevention of endoscopic tNSAID 
ulcers at 1 month,43–48 and 5 trials with 1,005 patients assessed 
these outcomes at 3 months or longer.44,47,49–51 Standard dose 
H2RAs are effective at reducing the risk of duodenal ulcers (RR 
0.24; 95% CI 0.10 to 0.57, and RR 0.36; 95% CI 0.18 to 0.74 at 
1 and 3 or more months respectively), but not of gastric ulcers 
(NS). One study did not have a placebo comparator and was 
not included in the pooled estimate.51
Three RCTs with 298 patients assessed the efficacy of 
double dose H2RA for the prevention of tNSAID induced 
upper GI toxicity.47,52,53 Double-dose H2RAs when compared 
to placebo were associated with a statistically significant 
reduction in the risk of both duodenal (RR 0.26; 95% CI 0.11 
to 0.65) and gastric ulcers (RR 0.44; 95% CI 026 to 0.74). 
This 56% relative risk reduction in gastric ulcer corresponds 
to a 12% absolute risk difference (from 23.1% to 11.3%) 
(Figures 3 and 4). Analysis of the secondary prophylaxis 
studies alone yielded similar results.
Symptoms
H2RA, in standard or double doses, were not associated with 
an excess risk of total drop-outs, dropouts due to side effects, 
Study or Subgroup
5.8.1 Misoprostol 400 µg/day
Agrawal22
Bolten24
Delmas28
Raskin36
Verdickt42
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.17, df = 4 (P = 1.00); I² = 0%
Test for overall effect: Z = 1.01 (P = 0.31)
5.8.2 Misoprostol 600 µg/day
Raskin36
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
5.8.3 Misoprostol 800 µg/day
Agrawal21
Delmas28
Elliott29
Graham31
Hawkey33
Raskin36
Roth38
Saggioro39
Silverstein40
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 14.18, df = 8 (P = 0.08); I² = 44%
Test for overall effect: Z = 9.33 (P < 0.00001)
Events
11
11
5
55
18
100
56
56
31
10
5
38
23
46
9
6
1210
1378
Total
193
178
73
462
164
1070
474
474
179
80
40
320
297
228
60
82
4404
5690
Events
9
10
6
49
15
89
49
49
16
6
1
34
3
49
2
1
896
1008
Total
191
183
103
454
175
1106
454
454
177
103
43
323
155
454
53
84
4439
5831
Weight
10.3%
11.2%
5.7%
56.3%
16.5%
100.0%
100.0%
100.0%
1.6%
0.5%
0.1%
3.4%
0.4%
3.3%
0.2%
0.1%
90.3%
100.0%
M-H, Fixed, 95% CI
1.21 [0.51, 2.85]
1.13 [0.49, 2.60]
1.18 [0.37, 3.71]
1.10 [0.77, 1.59]
1.28 [0.67, 2.46]
1.15 [0.88, 1.51]
1.09 [0.76, 1.57]
1.09 [0.76, 1.57]
1.92 [1.09, 3.38]
2.15 [0.81, 5.66]
5.38 [0.66, 44.04]
1.13 [0.73, 1.74]
4.00 [1.22, 13.12]
1.87 [1.29, 2.71]
3.98 [0.90, 17.58]
6.15 [0.76, 49.94]
1.36 [1.26, 1.47]
1.41 [1.31, 1.51]
Treatment Control Risk Ratio Risk Ratio
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Study or Subgroup
8.1.1 High dose
Hudson52
Taha47
Wolde53
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.06, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.13 (P = 0.002)
8.1.2 Low dose
Ehsanullah44
Levine49
Swift50
Taha47
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.54, df = 3 (P = 0.67); I² = 0%
Test for overall effect: Z = 1.55 (P = 0.12)
Events
7
7
3
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0
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Total
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6
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7
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1
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Total
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248
8
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Weight
41.7%
42.6%
15.7%
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13.4%
52.6%
3.7%
30.4%
100.0%
M-H, Fixed, 95% CI
0.44 [0.20, 0.94]
0.42 [0.18, 0.97]
0.50 [0.15, 1.64]
0.44 [0.26, 0.74]
1.11 [0.41, 2.97]
0.71 [0.41, 1.23]
0.18 [0.01, 3.91]
0.67 [0.33, 1.37]
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Treatment Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
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Favors treatment Favors control
Figure 3 H2RAs compared to placebo for the prevention of gastric ulcer.   Analysis by dose in studies of 12 weeks or longer duration.
Study or Subgroup
8.2.1 High dose
Hudson52
Taha47
Wolde53
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.44, df = 2 (P = 0.49); I² = 0%
Test for overall effect: Z = 2.87 (P = 0.004)
8.2.2 Low dose
Ehsanullah44
Levine49
Taha47
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.15, df = 2 (P = 0.34); I² = 7%
Test for overall effect: Z = 2.78 (P = 0.005)
Events
3
2
0
5
2
5
3
10
Total
39
97
15
151
151
248
95
494
Events
6
10
4
20
10
7
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27
Total
39
93
15
147
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248
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Weight
29.0%
49.3%
21.7%
100.0%
37.3%
25.7%
37.1%
100.0%
M-H, Fixed, 95% CI
0.50 [0.13, 1.86]
0.19 [0.04, 0.85]
0.11 [0.01, 1.90]
0.26 [0.11, 0.65]
0.19 [0.04, 0.87]
0.71 [0.23, 2.22]
0.29 [0.08, 1.03]
0.36 [0.18, 0.74]
Treatment Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
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Figure 4 H2RAs compared to placebo for the prevention of duodenal ulcer.   Analysis by dose in studies of 12 weeks or longer duration.
or symptoms compared to placebo. However, high-dose 
H2RAs significantly reduced symptoms of abdominal pain 
when compared to placebo (RR 0.57, 95% CI 0.33 to 0.98).
PPis
Six RCTs with 1,259 patients assessed the effect of PPIs on 
the prevention of NSAID-induced upper GI toxicity.32,33,54–57
PPIs significantly reduced the risk of both endoscopic 
duodenal (RR 0.20; 95% CI 0.10 to 0.39) and gastric ulcers 
(RR 0.39; 95% CI 0.31 to 0.50) compared to placebo 
(Figures 5 and 6).32,33,54–57 The results were similar for both 
primary and secondary prophylaxis trials.
Symptoms
Four omeprazole trials used the same composite endpoints 
to define treatment success.33,55,56,58 In these trials omeprazole 
significantly reduced “dyspeptic symptoms” as defined by 
the authors. In the combined analysis, drop-outs overall Drug, Healthcare and Patient Safety 2009:1 55
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(RR 0.89; 95% CI 0.62 to 1.29) and drop-outs due to side 
effects (RR 1.20; 95% CI 0.66 to 2.15) were not different 
from placebo.
Head to head comparisons  
of gastroprotective agents
Misoprostol vs H2RAs
Two trials with 600 patients compared misoprostol (400 to 
800 µg) to ranitidine 150 mg twice daily.36,41 Misoprostol 
appears superior to standard dose ranitidine for the prevention 
of tNSAID induced gastric ulcers (RR 0.12; 95% CI 
0.03 to 0.51) but not for duodenal ulcers (RR 1.00; 95% CI 
0.14 to 7.14).
PPi vs H2RAS
Yeomans et al in a 12-week study of 425 patients, compared 
omeprazole 20 mg daily to ranitidine 150 mg twice daily for 
tNSAID prophylaxis (various tNSAIDs used).58 In this study, 
omeprazole was superior to standard-dose ranitidine for the 
prevention of both gastric (RR 0.32; 95% CI 0.17 to 0.62) 
and duodenal ulcers (RR 0.11; 95% CI 0.01 to 0.89).
PPi vs misoprostol
Four trials with a total of 1,478 patients13,32,33,35 compared 
a PPI to misoprostol. Two studies compared low-dose 
misoprostol (400 µg) daily to a standard-dose PPI13,33 while 
the Graham study compared high-dose misoprostol (800 µg) 
to lansoprazole 15 or 30 mg daily. PPIs are superior to 
misoprostol for the prevention of duodenal (RR 0.25; 95% 
CI 0.11 to 0.056), but not gastric (RR 1.61; 95% CI 0.88 
to 3.06, random effects) or total gastroduodenal ulcers 
(RR 0.90; 95% CI 0.47 to 1.72, random effects).
Symptoms
In the two head to head comparison of omeprazole and 
misoprostol,32,33 PPIs were associated with significantly less 
drop-outs overall (RR 0.71; 95% CI 0.52 to 0.97), as well 
as significantly less drop-outs due to side effects (RR 0.48; 
09% CI 0.29 to 0.78). Compared to H2RA used for less than 
2 months, misoprostol caused significantly more drop-outs 
due to abdominal pain (RR 3.00, 95% CI 1.11 to 8.14) and 
more symptoms of diarrhea (RR 2.03, 95% CI 1.38 to 2.99). 
There were no significant differences in drop-outs due to 
Study or Subgroup
Bianchi Porro54
Cullen55
Ekstrom56
Graham32
Hawkey33
Lai57
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.64, df = 5 (P = 0.75); I² = 0%
Test for overall effect: Z = 7.79 (P < 0.00001)
Events
7
3
2
45
35
1
93
Total
43
83
86
236
274
22
744
Events
5
9
6
54
50
7
131
Total
23
85
91
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21
486
Weight
3.9%
5.4%
3.5%
44.3%
38.5%
4.3%
100.0%
M-H, Fixed, 95% CI
0.75 [0.27, 2.10]
0.34 [0.10, 1.22]
0.35 [0.07, 1.70]
0.39 [0.28, 0.54]
0.40 [0.27, 0.58]
0.14 [0.02, 1.02]
0.39 [0.31, 0.50]
Treatment Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
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Figure 5 Proton pump inhibitors compared to placebo for the prevention of gastric ulcer in studies of 8 weeks or longer duration.
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Figure 6 Proton pump inhibitors compared to placebo for the prevention of duodenal ulcer in studies of 8 weeks or longer duration.Drug, Healthcare and Patient Safety 2009:1 56
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side effects (RR 1.90, 95% CI 0.77 to 4.67) or symptoms 
of abdominal pain or diarrhea between low-dose H2RAs 
and PPIs.
Part II – COX-2 inhibitors
The search strategy identified 1,169 studies. Of these, 
255 references were rated as potentially relevant and the 
full articles were retrieved. Sixty studies met the inclu-
sion criteria, including 4 unique studies obtained from the 
new drug submission documents on the FDA web site.59–63 
An additional 5 “combined analyses studies” were identified 
by the search strategy and were included for the clinical ulcer 
complication endpoint (Table 2).64–68
Quality scores of the 60 included trials ranged between 
4 to 5 in 47 and between 2 to 3 in 22 studies. Removal of 
quality score 2 studies did not influence overall results. The use 
of allocation concealment was implied in all of the included 
trials, but was adequately described in only 6 studies.
Endoscopic ulcers were the measured endpoints of 
17 studies.59–61,63,69–81 Eleven COX-2 studies,78,82–91 and 
5 combined analyses65–68,92 reported on the outcome of clinical 
GI events (POBs or PUBs).
The remaining trials were either safety or tolerability 
studies or examined the clinical efficacy of COX-2s compared 
to tNSAIDS, but allowed for extraction of GI tolerability 
data.62,67,88,93–111 FDA study data are only presented as part 
of sensitivity analyses. Results specifically pertaining to 
meloxicam are not included herein.
endoscopic ulcer trials
CoX-2s vs non-selective NSAiDs
Seventeen studies with over 10,000 patients assessed 
the proportion of patients who developed endoscopic 
ulcers  while  taking  a  COX-2  compared  to  those 
taking a tNSAID.59–61,63,69–79,81 Seven studies assessed 
celecoxib,59,60,69–71,75,81 3 assessed rofecoxib,72–74 2 assessed 
etoricoxib,78,79 5 that assessed valdecoxib,61,63,76,77,80 and 
2 assessed lumiracoxib.75,81 Some studies assessed more 
than one intervention.75,81
endoscopically detected gastro-duodenal ulcers
Thirteen studies with a total of 7,839 patients showed a 74% 
relative risk reduction (RRR ) in combined gastro-duodenal 
ulcers with COX-2s vs tNSAIDs (RR 0.26; 95% CI 0.23 to 
0.30).69–80,112 This represented a 16% absolute risk reduction 
(ARR). Addition of the FDA studies did not significantly 
alter the results (RR 0.28; 95% CI 0.24 to 0.32). The results 
analyzed by the dose of COX-2s gave similar results. Results 
below are for “any dose” combined.
Eleven studies with a total of 6,726 patients compared the 
safety of a COX-2 to a comparator tNSAID for endoscopic 
gastric ulcers.69–77,80,112 The use of a COX-2 in this setting 
was associated with a 79% RRR in gastric ulcers (RR 0.21; 
95% CI 0.18 to 0.25) (Figure 7). This represented a 14% 
ARR in gastric ulcers with the use of COX-2s compared with 
tNSAIDs. Addition of the FDA studies did not significantly 
alter the results (RR 0.26; 95% CI 0.22 to 0.30).
The same 11 studies also compared the proportions 
of duodenal ulcers that occurred while using a COX-2 vs 
a tNSAID.69–77,80,112 Compared to using a tNSAID, the use 
of a COX-2 was associated with a 66% RRR in duodenal 
ulcers (RR 0.34; 95% CI 0.25 to 0.45) (Figure 7). This 
represented a 3% ARR. Addition of the FDA studies did 
not significantly alter the results (RR 0.29; 95% CI 0.23 
to 0.38) Keeping in mind that tNSAID related gastric 
ulcers were more commonly observed than duodenal ulcer, 
a trend was observed for greater RRR and ARR in gastric 
ulcers than for duodenal ulcers with COX-2s, compared to 
tNSAIDs (RR 0.21 vs 0.34, ARR of 14% vs 3%). This trend 
was consistent when celecoxib, rofecoxib and valdecoxib 
were analyzed separately.   Analysis by duration The data presented 
above are for any dose and duration up to 6 months. Subgroup 
analysis of these studies on the basis of duration (1 to 3 months 
and 3 to 6 months) did not significantly alter the results.
Analysis by COX-2
Analyses stratified by the individual COX-2s showed that 
each of the studied agents were safer than comparator 
tNSAIDs (Figure 8).
Celecoxib
Five studies with a total of 2,439 patients compared celecoxib 
to non-selective NSAIDs, showing a 79% RRR in total 
gastro-duodenal ulcers (RR 0.21; 95% CI 0.16 to 0.28) 
with celecoxib.69–71,75,112 Similar RRR were observed for 
gastric ulcers (RR 0.20; 95% CI 0.14 to 0.28) and duodenal 
ulcers alone (RR 0.29; 95% CI 0.18 to 0.47), as well as 
when the FDA studies were included (RR 0.26; 95% CI 
0.21 to 0.32).
Rofecoxib
Three studies with a total of 1,526 patients compared rofecoxib 
to non-selective NSAIDs.72–74 In this case, a 74% RRR was 
seen with rofecoxib (RR 0.26; 95% CI: 0.21 to 0.32). The 
results were similar when FDA studies were added to the 
analysis as well as when the analysis was done only for gastric 
ulcers (RR 0.20; 95% CI 0.15 to 0.26) and duodenal ulcers 
alone (RR 0.36; 95% CI 0.14 to 0.93, random effects).Drug, Healthcare and Patient Safety 2009:1 57
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Table 2 COX-2 included studies
Endpoint Study Comparisons  Number 
of patients
Mean 
age
Arthritis 
type
Follow-up
Intervention Comparator
Endoscopic 
ulcer
Celecoxib
emery70 200 mg bid diclofenac 75 mg bid 655 55 RA 24 weeks
FDA, 021 50 mg bid, 100 mg bid,  
200 mg bid
naproxen 500 mg bid; 
placebo
1,108 unk OA 2, 6, 12 weeks
FDA, 071 200 mg bid diclofenac 75 mg bid; 
ibuprofen 800 mg tid
1,097 unk OA and RA 4, 8, 12 weeks
Goldstein69 200 mg bid naproxen 500 mg bid 537 57 OA and RA 4, 8, 12 weeks
Simon71 100 mg bid, 200 mg bid,  
400 mg bid
naproxen 500 mg bid; 
placebo
1,149 54 RA 2, 6, 12 weeks
Rofecoxib
Hawkey73 25 mg/day, 50 mg day ibuprofen 800 mg tid 775 62 OA 6 weeks, 3, 6 months
Hawkey74 50 mg/day naproxen 500 mg bid; 
placebo
660 51.7 RA 3, 6, 9, 12 weeks
Laine72 25 mg/day, 50 mg/day ibuprofen 800 mg tid 742 62 OA 6 weeks, 3, 6 months
Etoricoxib
Hunt78 – multiple 120 mg/day ibuprofen 800 mg tid 680 62 OA 3, 6, 9, 12 weeks
Hunt79 –  
naproxen
120 mg/day naproxen 500 mg bid; 
placebo
742 54 OA and RA 3, 6, 9, 12 weeks
Valdecoxib
FDA 047 20 mg bid, 40 mg bid naproxen 500 mg bid 1,217 56 OA and RA 26 weeks
FDA 063 10 mg/day, 20 mg/day diclofenac 75 mg bid 784 unk OA 1, 2, 4, 6 weeks
Kivitz80 5 mg/day, 10 mg/day,  
20 mg/day
naproxen 500 mg tid; 
placebo
1,019 60 OA 2, 6, 12 weeks
Sikes76 10 mg/day, 20 mg/day ibuprofen 800 mg tid; 
diclofenac 75 mg bid; 
placebo
1,052 60 OA 2, 6, 12 weeks
Lumiracoxib
Hawkey74,113 lumiracoxib 200 mg/day,  
400 mg/day; celecoxib 
200 mg/day
ibuprofen 800 mg tid 1,042 58.7 OA 4, 8, 13 weeks
Kivitz81 lumiracoxib 400 mg/day,  
800 mg/day; celecoxib 
200 mg bid
ibuprofen 800 mg tid 893 51.7 RA 8, 13 weeks
Clinical ulcer 
complications
Celecoxib
Goldstein92 com-
bined analysis 
study
25 mg bid to 400 mg bid naproxen 500 mg bid; 
diclofenac 75 mg bid; 
ibuprofen 800 mg tid; 
placebo
11,008 59 OA and RA 2 to 24 weeks
Silverstein82 400 mg bid diclofenac 75 mg bid; 
iboprofen 800 mg tid
8,059 60 OA and RA 4, 13, 26 weeks  
(1 year FDA)
Singh91 Success-1 100 mg bid, 200 mg bid naproxen 500 mg bid 13,274 62 OA 6, 12 weeks
Zhao89 50 mg bid, 100 mg bid, 
200 mg bid
naproxen 500 mg bid: 
placebo
1,004 62.2 OA 2, 6, 12 weeks
Rofecoxib
Bombardier83 50 mg/day naproxen 500 mg bid 8,076 58 RA 4, 8, 12 months
Geusens90 25 mg/day, 50 mg/day naproxen 500 mg bid; 
placebo
1,023 53.6 RA 2, 4, 8, 12 weeks
(Continued)Drug, Healthcare and Patient Safety 2009:1 58
Rostom et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 2 (Continued)
Endpoint Study Comparisons  Number 
of patients
Mean 
age
Arthritis 
type
Follow-up
Intervention Comparator
Langman66 
combined 
analysis study
25 mg/day, 50 mg/day ibuprofen 800 mg tid; 
diclofenac 50 mg tid; 
nabumetone  
1,500 mg/day
5,435 63 OA 6 weeks, 4, 6, 12,  
24 months
Lisse88 25 mg/day naproxen 500 mg bid 5,597 63 OA 3, 6, 9, 12 weeks
Saag101 12.5 mg/day, 25 mg/day ibuprofen 800 mg tid 736 61 OA 2, 4, 6 weeks
Saag101 12.5 mg/day, 25 mg/day diclofenac 50 mg tid 693 62 OA up to 1 year
Etoricoxib
Leung87 60 mg/day naproxen 500 mg bid; 
placebo
501 63 OA 2, 4, 8, 12 weeks
Ramey68 
combined 
analysis study
5 to 120 mg/day diclofenac 150 mg/day; 
naproxen 1000 mg/day; 
ibuprofen 2400 mg/day
5,441 56.7 OA and RA up to 190 weeks
Laine116 MeDAL 60 or 90 mg/day diclofenac 150 mg/day 34 701 63 OA and RA up to 36 months
Valdecoxib
Goldstein92 
combined 
analysis study
5 to 80 mg/day naproxen 500 mg bid; 
diclofenac 75 mg bid; 
ibuprofen 800 mg tid; 
placebo
7,445 58.1 OA and RA up to 26 weeks
Lumiracoxib
Schnitzer86 
TARGeT
400 mg/day naproxen 500 mg bid; 
ibuprofen 800 mg tid
18,244 63.5 OA 4, 13, 20, 26, 39,  
52 weeks
COX-2 and PPI
Chan118 celecoxib 200 mg bid diclofenac 75 mg + 
omeprazole 20 mg
287 67 OA and RA 24 weeks
Lai119 celecoxib 200 mg daily naproxen 250 mg tid + 
lansoprosol 30 mg
142 57 OA and RA 24 weeks
Chan120 celecoxib 200 mg bid celecoxib 200 mg bid; 
esomeprazole  
20 mg bid
271 71 OA and RA 52 weeks
Tolerability Celecoxib
Bensen95 50 mg bid, 100 mg bid, 
200 mg bid
naproxen 500 mg bid; 
placebo
1,003 62 OA 2, 6, 12 weeks
Geba102 celecoxib 200 mg/day; 
rofecoxib 12.5 mg/day, 
25 mg/day
acetaminophen  
4000 mg/day
382 63 OA 2, 4, 6 weeks
Kivitz122 100 mg/day, 200 mg/day, 
400 mg/day
naproxen 500 mg bid; 
placebo
1,061 62.6 OA 2, 6, 12 weeks
McKenna104 100 mg bid diclofenac 50 mg tid; 
placebo
600 62 OA 2, 6 weeks
McKenna105 celecoxib 200 mg/day; 
rofecoxib 25 mg/day
placebo 182 62 OA 3, 6 weeks
whelton103 celecoxib 200 mg/day; 
rofecoxib 25 mg/day
none 811 74 OA 1, 2, 6 weeks
williams94 200 mg/day placebo 686 63 OA 2, 6 weeks
williams142 100 mg bid, 200 mg/day placebo 718 61.5 OA 2, 6 weeks
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Table 2 (Continued)
Endpoint Study Comparisons  Number 
of patients
Mean 
age
Arthritis 
type
Follow-up
Intervention Comparator
Rofecoxib
Cannon98 12.5 mg/day 25 mg/day diclofenac 50 mg tid 784 64 OA up to 1 year
Day97 12.5 mg/day, 25 mg/day ibuprofen 800 mg tid 809 64 OA 2, 4, 6 weeks
ehrich99 25 to 125 mg/day placebo 219 64 OA 1, 2, 4, 6 weeks
Myllykangas121 12.5 mg/day naproxen 500 mg bid 944 61.6 OA 2, 4, 6 weeks
Schnitzer100 5 to 50 mg/day placebo 658 55 RA 2, 4, 8 weeks
Truitt96 12.5 mg/day, 25 mg/day nabumetone  
1500 mg/day; placebo
341 83 OA 1, 2, 4, 6 weeks
Etoricoxib
Collantes110 90 mg/day naproxen 500 mg bid; 
placebo
891 52 RA 2, 4, 8, 12 weeks
Gottesdiener108 Part 1: 5 to 90 mg/day 
Part 2: 30 mg/day,  
60 mg/day 90 mg/day
Part 1: placebo Part 2: 
diclofenac 50 mg tid
617 60 OA 1, 2, 4, 6, 8, 14 weeks
Matsumoto111 90 mg/day naproxen 500 mg bid; 
placebo
816 56 RA 2, 4, 8, 12 weeks
wiesenhutter123 30 mg/day ibuprofen 2400 mg/day; 
placebo
258 61.3 OA 1, 2, 4, 6 weeks
Zacher109 60 mg/day diclofenac 50 mg tid 516 63 OA 2, 4, 6, 8 weeks
Valdecoxib
Bensen107 10 mg/day, 20 mg/day,  
40 mg/day
naproxen 500 mg bid; 
placebo
1,090 55 RA 4, 8, 12 months
FDA 061 10 mg/day, 20 mg/day,  
40 mg/day
naproxen 500 mg bid; 
placebo
1,093 57 RA 12 weeks
Makarowski106 5 mg/day, 10 mg/day naproxen 500 mg bid; 
placebo
513 68 OA 3 weeks
Pavelka77 20 mg/day, 40 mg/day diclofenac 75 mg bid 722 56 RA 2, 6, 8, 12, 18,  
26 weeks
Lumiracoxib
Geusens124 200 mg/day, 400 mg/day naproxen 500 mg bid 1,124 71 RA 2, 4, 13, 20, 26 weeks
Grifka125 200 mg/day, 400 mg/day placebo 594 61.9 OA 2, 4, 6 weeks
Lehmann126 100 mg/day, 100 mg/day 
with 200 mg loading 
dose for first 2 weeks; 
celecoxib 200 mg/day
placebo 1,684 62.4 OA 2, 4, 8, 13 weeks
Schnitzer86 50 mg bid, 100 mg bid, 
200 mg bid, 400 mg bid
diclofenac 400 mg bid; 
placebo
583 60.3 OA 4 weeks
Schnitzer86 50 mg bid, 100 mg bid, 
200 mg bid, 400 mg bid
diclofenac 400 mg bid; 
placebo
569 54.4 RA 2, 6, 12 weeks
Tannenbaum141 lumiracoxib 200 mg/day, 
400 mg/day; celecoxib 
200 mg/day
placebo 1,702 64.3 OA 2, 4, 8, 13 weeks
Abbreviations: unk, unknown; OA, osteoarthritis; PPi, protein pump inhibitors; RA, rheumatoid arthritis.Drug, Healthcare and Patient Safety 2009:1 60
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Study or Subgroup
1.6.7 Gastric ulcers total
Emery70
Goldstein69
Hawkey73
Hawkey74
Hawkey75
Kivitz80
Kivitz81
Laine72
Pavelka77
Sikes76
Simon71
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 6.54, df = 10 (P = 0.77); I² = 0%
Test for overall effect: Z = 17.28 (P < 0.00001)
1.6.8 Duodenal ulcers total
Emery70
Goldstein69
Hawkey73
Hawkey74
Hawkey75
Kivitz80
Kivitz81
Laine72
Pavelka77
Sikes76
Simon71
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 13.49, df = 10 (P = 0.20); I² = 26%
Test for overall effect: Z = 7.38 (P < 0.00001)
1.6.9 Combined total
Emery70
Goldstein69
Hawkey73
Hawkey74
Hawkey75
Hunt78 − multiple
Hunt79 − naprox
Kivitz80
Kivitz81
Laine72
Pavelka77
Sikes76
Simon71
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 8.67, df = 12 (P = 0.73); I² = 0%
Test for overall effect: Z = 19.61 (P < 0.00001)
Events
5
13
30
13
20
16
14
17
10
11
17
166
4
9
15
2
9
5
4
5
12
3
6
74
8
20
42
15
29
13
11
21
19
44
22
14
23
281
Total
212
269
369
219
763
547
419
364
483
299
423
4367
212
269
369
219
763
547
632
364
483
299
423
4580
212
269
369
219
763
216
235
547
632
364
483
299
423
5031
Events
24
76
85
48
22
16
29
40
31
40
29
440
15
19
10
11
20
2
2
10
14
13
8
124
33
89
88
56
39
24
43
18
27
76
45
49
36
623
Total
218
267
187
220
248
183
199
167
239
294
137
2359
218
267
187
220
248
183
199
167
239
294
137
2359
218
267
187
220
248
215
234
183
199
167
239
294
137
2808
Weight
4.4%
14.2%
21.0%
8.9%
6.2%
4.5%
7.3%
10.2%
7.7%
7.5%
8.1%
100.0%
9.7%
12.5%
8.7%
7.2%
19.9%
2.0%
2.0%
9.0%
12.3%
8.6%
8.0%
100.0%
4.3%
11.8%
15.4%
7.4%
7.8%
3.2%
5.7%
3.6%
5.4%
13.8%
8.0%
6.5%
7.2%
100.0%
M-H, Fixed, 95% CI
0.21 [0.08, 0.55]
0.17 [0.10, 0.30]
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etoricoxib
Two studies, with a total of 900 patients compared etoricoxib 
to non-selective NSAIDs using the endpoint of endoscopic 
gastro-duodenal ulcers.78,79 These trials demonstrated a 64% 
RRR (RR 0.37; 95% CI 0.18 to 0.77, random effects) with 
etoricoxib.
valdecoxib
Three studies compared valdecoxib to non-selective 
NSAIDs in 2,045 patients and demonstrated a 70% RRR in 
gastro-duodenal ulcers (RR 0.29; 95% CI 0.21 to 0.39) with 
valdecoxib.76,77,80 Similar RRR were observed when the analysis 
was done for gastric ulcers (RR 0.24; 95% CI 0.18–0.37) and 
duodenal ulcers alone (RR 0.39; 95% CI 0.21 to 0.70), and 
when the FDA studies were included in the gastro-duodenal 
ulcers analysis (RR 0.30; 95% CI 0.24 to 0.39).
Lumiracoxib
Two studies with a total of 1,376 patients compared lumi-
racoxib to non-selective NSAIDs.112,113 Lumiracoxib was 
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associated with a 74% RRR in gastro-duodenal ulcers 
(RR 0.26; 95% CI 0.18 to 0.39). Similar results were observed 
for gastric ulcers (RR 0.25; 95% CI 0.16 to 0.40) and 
duodenal ulcers (RR 0.20; 95% CI 0.09 to 0.43) when they 
were considered alone.
Analysis by comparator NSAiDs
Naproxen
Five studies compared either celecoxib or valdecoxib to 
naproxen in 2,734 patients. These showed a 75% RRR in 
endoscopic gastro-duodenal ulcers in favor of the COX-2s 
(RR 0.25; 95% CI 0.20 to 0.32). Results were similar when 
the FDA studies were included in the analysis (RR 0.27; 95% 
CI: 0.22 to 0.32).69,71,74,79,80
ibuprofen
Six studies which enrolled over 3,800 patients (2 rofecoxib,72,73 
1 etoricoxib,78 2 lumiracoxib,112,113 and 1 valdecoxib76) 
showed a 73% RRR in gastro-duodenal ulcers with COX-2s 
compared with ibuprofen (RR 0.27; 95% CI 0.23 to 0.32). 
Results were similar when the FDA studies were included in 
the analysis (RR 0.28; 95% CI 0.23 to 0.32).
Diclofenac
Three studies which enrolled a total of 1,596 patients 
demonstrated a 75% RRR in gastro-duodenal ulcers with 
COX-2s compared to diclofenac (RR 0.25; 95% CI 0.18 
to 0.35). This effect was somewhat reduced when the FDA 
studies were included in the analysis (RR 0.36; 95% CI 0.27 
to 0.47).70,76,77
Similar results were obtained when individual COX-2s 
were compared with the individual non-selective NSAIDs.
COX-2s vs placebo
Eight studies with a total of 4,081 patients compared 
low- and high-dose COX-2s to placebo.71–74,76,78–80 Low 
dose COX-2s appeared to demonstrate no greater risk of 
gastric or gastro-duodenal ulcers than placebo. However, 
high doses of COX-2s appeared to raise the relative risk of 
gastric (RR 1.22; 95% CI 0.83 to 1.80), duodenal (RR 1.29; 
95% CI 0.63 to 2.66), and combined gastro-dudenal ulcers 
(RR 1.57; 95% CI 0.96 to 2.56, random effects), though 
these trends missed statistical significance. Clinical GI 
events COX-2s vs non-selective NSAIDs Nine studies with 
a total of 94,294 patients assessed the safety of COX-2s by 
using the clinically important endpoint of ulcer complica-
tion, POB.65,66,68,82,83,92,114–116 Three of these trials studied 
celecoxib,82,92,115 2 studied rofecoxib,66,83 2 trials evaluated 
etoracoxib,68,116 and 1 each evaluated valdecoxib65 and 
lumiracoxib114 separately. Overall, the use of these COX-2s 
was associated with a 57% RRR in POBs (RR , 0.43; 95% 
CI 0.28 to 0.67, random effects), compared with using 
tNSAIDs. Removal of the combined analyses studies had 
no influence on the result (RR 0.39; 0.29 to 0.53) and the 
inclusion of the FDA 12-month CLASS study data117 did 
not alter the results (RR 0.42; 95% CI 0.33 to 0.54). The 
60% RRR in these analyses represents an ARR of 0.4% 
(Figure 9).
Fourteen studies compared COX-2s with tNSAIDs by 
using PUB as the study endpoint.65,66,68,78,82,83,87–90,92,114–116 
In this analysis, the use of a COX-2 was associated with 
a 57% RRR in PUBs (RR 0.43; 95% CI 0.34 to 0.55, 
random effects). Removal of the combined analyses studies 
eliminated the observed heterogeneity but had little effect on 
the point estimate (RR 0.49; 95% CI 0.41 to 0.58). Similarly, 
the use of the FDA CLASS data did not significantly 
alter the estimate (RR 0.42; 95% CI 0.33 to 0.53, random 
effects) (Figure 10).
Analyses stratified by cyclooxygenase-2s
Celecoxib
Four studies with 31,106 assessed the effect celecoxib 
vs non-selective NSAIDs on clinical GI events (POBs or 
PUBs).82,89,92 Celecoxib use was associated with a 77% RRR 
in POBs (RR 0.23; 95% CI 0.07 to 0.76, random effects) 
and a 61% RRR in PUBs (RR 0.39; 95% CI 0.21 to 0.73, 
random effects). Removal of the combined analyses study92 
eliminated the heterogeneity observed in both the POB (RR 
0.42; 95% CI 0.22 to 0.80) and PUBs (RR = 0.34; 95% 
CI 0.22 to 0.80) analyses. The use of the FDA 12-month 
CLASS data did not alter the RR estimates for POBs or 
PUBs significantly.
Rofecoxib
Four studies with 19,288 patients assessed the effect of 
rofecoxib vs non-selective NSAIDs on clinical GI events 
(POBs or PUBs).66,83,88,90 Rofecoxib use reduced the relative 
risk of POBs by 58% (RR 0.42; 95% CI 0.24 to 0.73) and 
the relative risk of PUBs by 56% (RR 0.44; 95% CI 0.34 to 
0.58). Removal of the combined analysis study did not alter 
the point estimates.
valdecoxib
One combined analysis study with 6,461 patients evaluated 
the effect of valdecoxib on POBs and PUBs.65 Valdecoxib 
reduced the relative risk of POBs by 65% (RR 0.35; 95% 
CI 0.14 to 0.87) and the relative risk of PUBs by 77% 
(RR 0.23; 95% 0.15 to 0.36).Drug, Healthcare and Patient Safety 2009:1 63
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etoricoxib
Four studies with 10,856 patients evaluated the effect 
of etoricoxib on POBs68,116 and PUBs.78,87 Etoricoxib 
demonstrated a nonsignificant trend in reducing the risk of 
POBs (RR 0.82; 95% CI 0.44 to 1.51, random effects), but 
it significantly reduced the RR of PUBs by 46% (RR 0.64; 
95% CI 0.42 to 0.96).
Lumiracoxib
One study with 18,244 patients demonstrated a significant 
64% RRR in POBs (RR 0.36; 95% CI 0.24 to 0.55) and 
a 44% RRR in PUBs (RR 0.56; CI 0.41 to 0.78) with the 
use of lumiracoxib, compared with using non-selective 
NSAIDs.114
Analysis by comparator NSAiDs
In general COX-2s appeared to maintain their safety 
advantage regardless of the comparator non-selective 
NSAID. COX-2s were statistically superior to naproxen 
(RR 0.34; 95% CI 0.24 to 0.48), and ibuprofen (RR 0.46; 
95% CI 0.30 to 0.71) for the POB endpoint. The data 
comparing COX-2s to diclofenac are predominately derived 
from 2 studies and heavily influenced by the CLASS trial 
data which showed no significant difference between 
celecoxib vs diclofenac.82,92 In the current analysis, celecoxib 
demonstrated a non-significant trend towards fewer POBs 
than diclofenac (RR 0.31; 95% CI 0.06 to 1.61) while a 
statistically significant 59% RRR in PUBs was observed 
(RR 0.41; 95% CI 0.30 to 0.55).
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Figure 9 POBs (perforation, obstruction or bleeding) with COX-2s vs tNSAiDs.
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COX-2s vs placebo
There are limited data, mostly derived from the combined 
analyses studies, comparing COX-2s with placebo for 
the clinical outcomes of POBs65,92 and PUBs.65,66,87,89,92 
In these analyses, the use of COX-2s was associated with 
non-significant trends toward an increased RR of POBs (RR 
2.66; 95% CI 0.34 to 20.95) and PUBs (RR 2.26; 95% CI 
0.96 to 5.33) (Figure 9).  These findings are supported by the 
APPROVe polyp prevention study which demonstrated that 
over a 3-year period, rofecoxib was associated with a statistically 
significant 4.9-fold increased risk of clinical ulcer complications 
compared to placebo.9 This study was not included in the main 
results since its population did not include arthritis patients. 
Influence of acetylsalicylic acid co-administration 
on clinically important ulcer complications
Five trials allowed assessment of the effects of the 
co-administration of ASA with a COX-2.65,82,91,114,116 In a 
pooled subgroup analysis of over 18,000 patients taking 
ASA, there was no statistically significant difference in the 
relative risk of ulcer complications (POBs) between those 
in the COX-2 arms and those in the non-selective arms of 
these trials (RR 0.93; 95% CI 0.68 to 1.27 for POBs). A small 
advantage of COX-2s over tNSAIDs cannot be ruled out by 
these results because this subgroup analysis might be under-
powered The PUB analysis showed a statistically significant 
benefit for COX-2 + ASA vs tNSAID +ASA (RR 0.72; 
95% CI 0.62 to 0.95), but data from one study could not 
be used in this analysis. In more than 40,000 patients in the 
COX-2 arms, patients taking ASA had a 3.46 (95% CI 2.44 
to 4.91) greater relative risk of POBs than COX-2 users not 
taking ASA. Among 34,000 patients in the tNSAID arms 
of these studies, those taking ASA had a 1.65 greater rela-
tive risk of POBs than those not taking ASA, although this 
result did not reach statistical significance (95% CI 0.76 
to 3.57). One must keep in mind that these are post-hoc 
subgroup analyses that might be subject to bias. Furthermore, 
the subgroup analysis within an tNSAID treatment group 
(eg, COX-2 vs COX-2 + ASA) represents a nonrandomized 
comparison in which differences could be influenced by fac-
tors other than ASA use (Figures 11 to 13).
Addition of a PPi to COX-2s
The comparative safety of a COX-2s compared to a tNSAID 
with a PPI has been addressed in high-risk patients with recent 
ulcer bleeding who were enrolled after ulcer healing and 
H. pylori eradication. Chan et al118 found recurrent ulcer bleeding 
at 6 months to be 4.9% with celecoxib 200 mg twice daily and 
6.4% with diclofenac 75 mg twice daily plus omeprazole 20 mg 
daily. Lai et al119 found recurrent ulcer complications (bleeding 
and 1 case of severe pain) in 3.7% with celecoxib 200 mg daily 
and 6.3% with naproxen 750 mg daily plus lansoprazole 30 mg 
daily at a median follow-up of 24 weeks. These results suggest 
high-risk patients have high rates of recurrent bleeding even with 
the protective strategy of a coxib or a tNSAID + PPI.
The combination of a coxib and PPI was assessed in the 
same high-risk population in a subsequent 1-year study by 
Chan et al120 Recurrent ulcer bleeding occurred in 9% with 
celecoxib alone vs zero with celecoxib plus twice daily 
esomeprazole. The MEDAL Program also demonstrated that 
a coxib plus PPI had significantly fewer upper GI clinical 
events (again, driven by a decrease in uncomplicated events) 
than a tNSAID plus PPI (RR 0.62, 0.45 to 0.83).116
Symptoms and treatment withdrawals
Treatment withdrawals as a result of GI side effects: COX-2s 
vs nonselective NSAIDs.
Twenty-one studies with close to 47,000 patients assessed 
the effect of COX-2s on patient withdrawals due to GI 
symptoms.61,69–71,79,82,83,87–90,95,98,101,106,109,110,111,115,121–123 Overall, 
compared to tNSAIDs, COX-2s were associated with a 
significantly lower relative risk of withdrawals due to GI 
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side effects (RR 0.65; 95% CI 0.57 to 0.73, random effects), 
withdrawals due to dyspepsia (RR 0.37; 95% CI 0.18 to 
0.74), and due to abdominal pain (RR 0.25; 95% CI 0.13 
to 0.49). Compared to placebo, low-dose COX-2s showed 
no statistically significant difference for these same endpoints, 
while high-dose COX-2s were associated with a small but 
significantly increased relative risk of drop-outs due to 
GI side effects (RR 1.74; 95% CI 1.13 to 2.68).
Adverse Gi symptoms with COX-2s compared  
with non-selective NSAiDs
Twenty-eight studies with close to 60,000 patients assessed the 
effect of low- or high-dose COX-2s compared to tNSAIDs for 
treatment related overall GI side effects, dyspepsia, nausea, and 
abdominal pain.69,70,75–77,82,86,87,89,90,96–98,101,104,106,107,111,112,114,122,124 
Low-dose COX-2s were associated with a lower relative risk 
of GI symptoms (RR 0.78; 95% CI 0.74 to 0.82); dyspepsia 
(RR 0.83; 95% CI 0.75 to 0.90); nausea (RR 0.72; 95% CI 
0.64 to 0.82); and abdominal pain (RR 0.64; 95% CI 0.58 to 
0.70). The results for high-dose COX-2s were similar.
Adverse Gi symptoms with COX-2s compared  
with placebo
Twenty studies with over 10,000 patients compared the 
occurrence of adverse GI symptoms between COX-2s 
and placebo. Low-dose COX-2s were associated with a slight 
but statistically significant increased relative risk of overall 
GI symptoms (RR 1.26; 95% CI 1.13 to 1.42); dyspepsia 
(RR 1.28; 95% CI 1.08 to 1.51); nausea (RR 1.24; 95% CI 
1.01 to 1.53); and abdominal pain (RR 1.24; 95% CI 1.02 
to 1.52).76,80,86,87,89,90,94,96,97,99,100,104,106–108,122,123–126 The results for 
high-dose COX-2s were similar.
Discussion
The results of this systematic review demonstrate that there 
are several therapeutic strategies available to reduce the 
incidence of tNSAID related upper GI harms. Large, well 
powered, studies have shown that strategies using a tNSAID 
with misoprostol, or the use of a COX-2 instead of a tNSAID, 
each reduce the incidence of endoscopically detected upper 
GI ulcerations, and clinically important upper GI events 
such as bleeding. Misoprostol in doses that prevent upper 
GI ulcer complications is associated with important adverse 
effects which may limit its long-term use. Standard doses of 
H2RAs reduce the incidence of duodenal ulcers but are not 
effective at reducing the incidence of gastric ulcers. Double 
doses of H2RAs and standard-dose PPIs reduce the incidence 
of duodenal as well as gastric ulcers, but because tachyphy-
laxis can occur with chronic H2RA use, a standard-dose PPI 
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Figure 12 Clinical ulcers (PUBs [perforation, obstruction, bleeding or the presence of a symptomatic ulcer]) with COX-2 + ASA vs COX-2 alone. 
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strategy is preferred. H2RAs and PPIs have not been directly 
assessed in large primary prevention clinical outcome studies 
powered to detect ulcer complications. However, in secondary 
prevention studies of high-risk GI patients, tNSAIDs with 
a PPI appear as effective as a COX-2 strategy at preventing 
clinical ulcer complications. In these high-risk patients, these 
strategies were still associated with important ulcer relapse 
rates, suggesting that both strategies may provide incomplete 
protection for the secondary prevention of tNSAID-related 
ulcers. However, a recent study has shown that a strategy of 
combining a PPI with a COX-2 was superior to a COX-2 
alone for the secondary prevention of ulcer complications, 
suggesting that a COX-2 + PPI strategy is the preferred 
strategy in high-risk GI patients. Further, the current meta-
analysis, supported by the APPROVe polyp prevention study,9 
has shown that while COX-2 offer greater GI safety than 
tNSAIDs as a group, COX-2 are associated with a statisti-
cally greater risk of clinical upper GI complications than 
those taking placebo.
The discovery that COX-2s are associated with impor-
tant cardiovascular harm has complicated the clinical use 
of NSAIDs significantly. Further, in Canada, all COX-2 
save celecoxib have been withdrawn from the market due 
to cardiovascular and other harms and it is unlikely that a 
new COX-2 would be released to market unless it is truly 
cardiovascularly neutral or it is combined with a GI-safe 
antithrombotic agent. During this time of uncertainty, when 
physicians were actively switching patients back to tNSAIDs + 
a gastropropective agent such as a PPI, it became increas-
ingly clear that non-naproxen tNSAIDs were also associated 
with important CVS harms.11 A meta-analysis by Kearney 
et al using an extensive set of RCT data derived from 
published and unpublished studies has suggested that, as 
a group, COX-2s are associated with an increased risk of 
CV outcomes when compared with placebo or naproxen, 
but not when compared with non-naproxen, non-ASA 
tNSAIDs11 suggesting that non-naproxen-tNSAIDs share 
the cardiovascular harms of COX-2s.
In light of the cardiovascular harm data relating to 
COX-2s, it is tempting to suggest combining these agents 
with ASA. However, the available data from this meta-
analysis suggest that this strategy would likely undermine 
the GI safety advantage of COX-2s. In patients taking ASA, 
we found no statistically significant difference in POBs or 
PUBs in patients randomized to a COX-2 or a tNSAID; 
however, the analyses did not stratify the randomization 
for ASA use. Thus, it is possible that other patient-related 
factors played a role in this result. Furthermore, although the 
analysis included about 7000 patients, it is still possible that 
a protective effect of COX-2s over tNSAIDs in this setting 
is present but not detected because of insufficient statistical 
power. We also found that the addition of ASA to a COX-2 
significantly increased the risk of a POB 4.12-times over a 
COX-2 alone, and that the addition of ASA to a tNSAID 
demonstrated a nonsignificant 1.27 increased risk of POBs 
over the use of a tNSAID alone. One needs to note that these 
analyses represent nonrandomized comparisons, and that 
the group sizes were somewhat uneven (more patients in 
the COX-2 or tNSAID alone groups than in the groups with 
ASA). Nonetheless, the results are not entirely unexpected, 
because it has been known for some time that concomitant use 
of multiple NSAIDs increases the risk of GI complications 
over a single NSAID alone. These results are also in keeping 
with an RCT by Laine et al127 revealing that the incidence of 
endoscopically detected ulcers with rofecoxib and low-dose 
ASA was not lower than that seen with ibuprofen alone. 
However, it is clear that further study in this area is required 
to verify the above findings, such as through a dedicated RCT 
or from individual patient data systematic reviews. Further, 
adding ASA to a COX-2 implies that the COX-2s will not 
interfere with the effect of ASA. However, this hypothesis 
also requires further study because there are suggestions that 
the use of a tNSAID might interfere with the action of ASA 
in this setting, although there appears to be less interference 
with selective COX-2s.128–132
When COX-2s were released, they promised an era of 
improved GI safety, as well as an era of greater clinical 
simplicity, with the option of prescribing a single low risk 
agent when chronic NSAID use was required. However, with 
the greater understanding of the GI, cardiovascular, and other 
end organ safety profile of tNSAIDs and COX-2s, clinicians 
must now stratify their patients on the basis of GI, cardio-
vascular, and other organ system risk factors and choose an 
NSAID strategy, that minimizes a patient’s overall risk. This 
has become especially difficult, for patients who are know to 
be at high risk of GI and cardiovascular harms.
When considering the treatment of an arthritic patient 
with a tNSAID or a COX-2, a clinician must consider the 
patient`s underlying GI, cardiovascular, and other organ risks 
factors. Further, low-dose ASA is recommended for patients 
at increased cardiovascular risk;133,134 therefore an algorithm 
considering-high cardiovascular risk patients needs to 
assume the use of low-dose ASA in such patients. The recent 
Canadian Consensus Conference on NSAIDs proposed the 
following recommendations;135 For patients with both low GI 
and cardiovascular risk, a tNSAID alone may be acceptable. Drug, Healthcare and Patient Safety 2009:1 67
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For patients with low GI risk and high cardiovascular risk, 
naproxen may be preferred because of the potential lower 
cardiovascular risk than with other tNSAIDs or COX-2s. 
However, since these patients are assumed to be on low-dose 
ASA therapy, the combination of naproxen plus ASA would 
increase the GI risk, and therefore, the addition of a gastro-
protective agent such as a PPI should be considered.
Long-term NSAID therapy can be more complex in 
patients with high GI risk. Testing for and eradicating 
Helicobacter pylori in patients at high risk of NSAID-related 
GI bleeding should be considered but will be insufficient 
without ongoing gastroprotection.57,136–139 In these patients, 
if cardiovascular risk is low, a COX-2 alone or a tNSAID 
with a PPI appear to offer similar protection from recurrent 
GI bleeding, but this protection is incomplete. Therefore, for 
patients at very high risk of upper GI events, a combination 
of a COX-2 plus a PPI may offer the best GI safety profile. 
When both GI and cardiovascular risks are high, the optimal 
strategy is to avoid NSAID therapy if at all possible. If the 
NSAID therapy is deemed necessary, then the clinician must 
prioritize the cardiovascular and GI risks, recognizing that 
these patients are likely taking ASA for their cardiovascular 
risk. If GI risk is the primary concern (ie, a very high-risk 
GI patient), a COX-2 plus a PPI is recommended. If the 
primary concern is cardiovascular risk, naproxen plus a PPI in 
patients on ASA would be preferred; however, GI risk should 
be closely monitored, as this strategy carries a higher GI risk 
than a COX-2 plus a PPI in patients on ASA.135
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